Abstract CT158: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory and transcriptionally addicted solid tumors
Year: 2024
Type: conference-abstract
Source: Cancer Research
Authors: Miguel Villalona Calero, Mark Agulnik, Monica Mita, Alain Mita, Noah Federman, Drew Rasco, David Spigel, Jia Luo, Glenn Hanna, Gregory Cote, Mohamad A. Salkeni, Rashmi Chugh, Natraj R. Ammakkanavar, Satish A. Shah, Amol Rao, Kamalesh Kumar Sankhala, Richard E. Cutler, Tressa Hood, Luis Carvajal, Crystal MacKenzie, Charles Lin, Jorge DiMartino, Elizabeth A. Olek, Brian Van Tine
Institutions: City Of Hope National Medical Center, Cedars-Sinai Medical Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, South Texas Accelerated Research Therapeutics, Sarah Cannon, Tennessee Oncology, Dana-Farber Cancer Institute, Massachusetts General Hospital, Virginia Cancer Specialists, University of Michigan, U-M Rogel Cancer Center, Washington University in St. Louis
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4393988535